Events

QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.

InSysBio announces their participation at 34th Annual Meeting & Pre-Conference Programs on Systems Biology (SITC 2019)

InSysBio announces their participation at Tenth American Conference on Pharmacometrics (ACoP10) to be held October 20th to 23rd, 2019, at the Rosen Shingle Creek Hotel in Orlando, FL.

InSysBio announces their participation at PAGE 2019 28th Meeting being held from 11 to 14 June 2019 in Stockholm, Sweden.

InSysBio announces their participation at 15th Essential Protein Engineering Summit being held on April 8-12 in Boston, MA.

InSysBio announces their participation at American Association for Cancer Research Annual Meeting 2019 being held on March 29 – April 3 in Atlanta, GA